Invitation Letter for Pneumococcal Conjugate Dose Ranging Study

First Page		Document Content
Date: 2013-02-15 09:44:33 Biology Microbiology Pneumococcal vaccine Pneumococcal conjugate vaccine Vaccination Pneumococcal polysaccharide vaccine Streptococcus pneumoniae Pneumococcal infection Vaccines Pneumonia Medicine		Invitation Letter for Pneumococcal Conjugate Dose Ranging Study Add to Reading List Source URL: www.grouphealthresearch.org Download Document from Source Website File Size: 21,81 KB Share Document on Facebook

	LASCCO Announces Positive Scientific Advice Meeting with MHRA and Plans a First-In-Man Clinical Trial with CAL02 in Patients with Severe Pneumococcal Pneumonia GENEVA, SWITZERLAND, 22 October 2014 – LASCCO SA has held DocID: 1rhtI - View Document
	HIN Logo_Color_Master_Standard Logo_CS2 DocID: 1qGRg - View Document
	ppsv - what you need to know- 508 compliant DocID: 1q1Yu - View Document
	Combioxin receives Clinical Trial Authorization to initiate a first-in-man study with CAL02 in patients with severe pneumococcal pneumonia GENEVA, SWITZERLAND, 12 January 2016 – Combioxin SA is pleased to announce that DocID: 1prxw - View Document
	BATTLING INFECTIONS OF THE CENTRAL NERVOUS SYSTEM Organisms, Risk Factors, and Laboratory Diagnostics Blake W. Buchan, PhD, D(ABMM) Email: Phone: DocID: 1oWg5 - View Document